Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase
21 Ottobre 2021 - 10:01PM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic
pharmaceutical company, today announced that Tom Mitro, President
and Chief Operating Officer presented an overview on Aerie’s
glaucoma franchise at the Ophthalmology Innovation Summit Glaucoma
Innovation Showcase. The slide presentation provides an update on
Aerie’s franchise growth in the United States, as well as progress
toward market entry in Europe and Japan.
The slide presentation from today’s event is available now and
may be accessed by visiting Aerie’s website at
http://investors.aeriepharma.com.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
ocular surface diseases and retinal diseases. Aerie’s first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eye drop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rhopressa®, including the product label, is available at
www.rhopressa.com. Aerie’s second product for the reduction of
elevated IOP in patients with open-angle glaucoma or ocular
hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic
solution) 0.02%/0.005%, the first and only fixed-dose combination
of Rhopressa® and the widely-prescribed PGA (prostaglandin analog)
latanoprost, was launched in the United States in May 2019. In
clinical trials of Rocklatan®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rocklatan®, including the product label, is available at
www.rocklatan.com. Aerie continues to focus on global expansion and
the development of additional product candidates and technologies
in ophthalmology, including for the treatment of dry eye disease,
wet age-related macular degeneration and diabetic macular edema.
More information is available at www.aeriepharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211021005089/en/
Ami Bavishi 908-947-3949; abavishi@aeriepharma.com
Grafico Azioni Aerie Pharmaceuticals (NASDAQ:AERI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Aerie Pharmaceuticals (NASDAQ:AERI)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Aerie Pharmaceuticals Inc (NASDAQ): 0 articoli recenti
Più Aerie Pharmaceuticals, Inc. Articoli Notizie